Kunming Biomed International (KBI) announces the hiring of Zhiming Ding, MD, Ph.D, as Chief Scientific Officer. "We welcome Zhiming joining our executive management team to further strengthen company's core competence in translational non-human primate (NHP) models in metabolic, cardiovascular and NASH/fibrosis spaces. Appointment of Dr. Ding reflects KBI's continuous commitment and dedication to providing high quality and science-based preclinical services, ultimately translating preclinical potential into clinical success to our collaborators", said Dr. Bob Zhang, CEO of KBI.

Dr. Zhiming Ding brings to KBI over 30 years' experience in biomedical field including 17 years in drug discovery. He has strong expertise in cardiovascular and metabolic diseases and extensive experience in project management and execution. He is the former Research Director and Head of in vivo pharmacology at Lilly China Research Center. He also served at Lexicon Pharmaceutical in the US as the Director of Cardiology/Metabolism. Dr. Ding received his MD and PhD in Toxicology from Tongji Medical University. He had his postdoctoral training at University of Texas at Austin and did research fellow at M.D. Anderson Cancer Center and Baylor College of Medicine.